Daclatasvir, simeprevir and ribavirin as a promising interferon-free triple regimen for HCV recurrence after liver transplant

Digestion

Volumn 91, Issue 4, 2015, Pages 326-333

  Herzer, Kerstin ^a,b,c   Papadopoulos Köhn, Angela ^a   Walker, Andreas ^c,d   Achterfeld, Anne ^a   Paul, Andreas ^b   Canbay, Ali ^a   Timm, Jörg ^c,d   Gerken, Guido ^a  

^a Department of Gastroenterology and Hepatology ^*  (Germany)

^b Visceral and Transplantation Surgery   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Daclatasvir; HCV recurrence; IFN free; Liver transplantation; Simeprevir

Indexed keywords

DACLATASVIR; EVEROLIMUS; MYCOPHENOLATE MOFETIL; RIBAVIRIN; SIMEPREVIR; TACROLIMUS; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL LABORATORY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HYPERHIDROSIS; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCREASED APPETITE; LIVER FUNCTION; LIVER GRAFT; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; VIREMIA; VIRUS LOAD; ANTIVIRAL RESISTANCE; CASE REPORT; COMBINATION DRUG THERAPY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER TRANSPLANTATION; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RIBAVIRIN; SIMEPREVIR; VIRAL LOAD; VIREMIA;

EID: 84929691994     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000382075     Document Type: Article

References (27)

1. Rubín A, Aguilera V, Berenguer M: Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35: 805-812.
2. Berenguer M: Viral hepatitis after liver transplantation. Hepatol Res 2007; 37(suppl 2): S279-S286.
3. Howell J, Angus P, Gow P: Hepatitis C recurrence: The Achilles heel of liver transplantation. Transpl Infect Dis 2014; 16: 1-16.
4. Berenguer M: Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
5. Kong Y, Wang X, Shang Y, Schroder PM, Liang W, Ling X, Guo Z, He X: Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: A meta-analysis. PLoS One 2012; 7:e52158.
6. Charlton M: Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail. Hepatology 2011; 54: 3-5.
7. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC: Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. J Hepatol 2014; 60: 78-86.
8. Zimmermann HW, Tacke F: The beginning of the end for interferon therapy-novel interferon-free treatment options for hepatitis C. Z Gastroenterol 2014; 52: 450-452.
9. Gane E: Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int 2011; 31(suppl 1):62-67.
10. Adler H, Lambert JS: Daclatasvir for the treatment of hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2014; 8: 725-738.
11. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M: Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012; 18: 1053-1059.
12. Takehara T: Simeprevir for the treatment of chronic hepatitis C genotype 1 infection. Expert Rev Anti Infect Ther 2014; 12: 909-917.
13. Timm J, Li B, Daniels MG, Bhattacharya T, Reyor LL, Allgaier R, Kuntzen T, Fischer W, Nolan BE, Duncan J, Schulze zur Wiesch J, Kim AY, Frahm N, Brander C, Chung RT, Lauer GM, Korber BT, Allen TM: Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology 2007; 46: 339-349.
14. Terrault N: Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012; 26: 531-548.
15. Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, Cornberg M, Wedemeyer H: The clinical significance of drug-drug interactions in the era of directacting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther 2013; 38: 1365-1372.
16. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-426.
17. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M: Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebocontrolled trial. Lancet 2014; 384: 403-413.
18. Belema M, Meanwell NA: Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. J Med Chem 2014; 57: 5057-5071.
19. Dhaliwal HS, Nampoothiri RV: Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014; 370: 1560.
20. Sulkowski MS, Jacobson IM, Nelson DR: Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014; 370: 1560-1561.
21. Asselah T: Daclatasvir plus sofosbuvir for HCV infection: An oral combination therapy with high antiviral efficacy. J Hepatol 2014; 61: 435-438.
22. Ollendorf DA, Tice JA, Pearson SD: The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection. JAMA Intern Med 2014; 174: 1170-1171.
23. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT: Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-1605.
24. Vermehren J, Sarrazin C: The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012; 26: 487-503.
25. Papadopoulos-Köhn A, Achterfeld A, Paul A, Canbay A, Timm J, Jochum C, Gerken G, Herzer K: Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. Transplantation 2015; 99: 841-847.
26. Herzer K, Papadopoulos-Köhn A, Timm J, Paul A, Jochum C, Gerken G: HCV reinfection after liver transplantation-management and first experiences with telaprevir-based triple therapy. Dtsch Med Wochenschr 2013; 138: 1759-1764.
27. Welzel TM, Zeuzem S: Interferon-free strategies without a nucleoside/nucleotide analogue. Semin Liver Dis 2014; 34: 47-57.